• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rubius Therapeutics to Provide Strategic Update

    9/12/22 4:30:00 PM ET
    $RUBY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RUBY alert in real time by email

    CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the Company plans to provide a strategic update and host an investor teleconference and webcast on Tuesday, September 13, 2022, at 7:30 a.m. EDT.

    Investor Teleconference & Webcast

    An audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website and can be directly accessed here. An archived webcast will be accessible for 90 days after the event.

    About Rubius Therapeutics

    Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to biologically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2022 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

    Investor and Media Contact

    Lori Murray, Chief Corporate Affairs Officer

    [email protected]



    Primary Logo

    Get the next $RUBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RUBY

    DatePrice TargetRatingAnalyst
    9/13/2022Buy → Neutral
    Guggenheim
    2/25/2022$14.00 → $5.00Market Perform
    SVB Leerink
    11/9/2021$20.00 → $14.00Market Perform
    SVB Leerink
    10/19/2021$25.00 → $22.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $RUBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Appelhans Dannielle sold $1,323 worth of shares (10,385 units at $0.13), closing all direct ownership in the company

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/27/23 6:08:34 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Cagnoni Pablo J sold $2,112 worth of shares (8,448 units at $0.25), decreasing direct ownership by 11% to 66,082 units to cover withholding tax

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/1/23 9:41:05 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Appelhans Dannielle converted options into 7,500 shares and sold $970 worth of shares (3,878 units at $0.25), increasing direct ownership by 54% to 10,385 units to satisfy withholding tax

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/1/23 9:40:03 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Financials

    Live finance-specific insights

    See more
    • Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

      CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeuti

      7/26/22 8:00:00 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics to Announce First Quarter 2022 Financial Results

      CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results on Tuesday, May 10, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™.

      4/26/22 8:00:00 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

      Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or Dose-Limiting Toxicities as of the Cutoff Date Expanding Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung Cancer and Renal Cell Carcinoma Management to Host Conference Call Today at 1:15 p.m. EDT to Discuss Clinical Data and Clinical Development Next Steps for RTX-240 CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create

      4/8/22 1:00:00 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    SEC Filings

    See more
    • SEC Form 15-12G filed by Rubius Therapeutics Inc.

      15-12G - Rubius Therapeutics, Inc. (0001709401) (Filer)

      4/10/23 4:17:29 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Rubius Therapeutics, Inc. (0001709401) (Filer)

      4/6/23 5:11:23 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 25 filed by Rubius Therapeutics Inc.

      25 - Rubius Therapeutics, Inc. (0001709401) (Filer)

      3/28/23 4:23:38 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

      SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)

      4/10/23 9:37:13 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

      SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)

      3/3/23 11:28:09 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

      SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)

      2/14/23 1:00:53 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

      Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of

      11/2/22 4:01:00 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

      Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform.  www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo

      10/17/22 9:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cellarity Announces Close of $121 Million Series C Financing

      Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, including Kyowa Kirin Co. Ltd. and Hanwha Impact Partners. The proceeds of the financing will be used to grow Cellarity's talent base, strengthen its platform, and advance its pipeline toward the clinic. "We welcome our new investors and appreciate the continued support of our current investors," said Fabrice Chouraqui, PharmD, CEO of Cellarit

      10/4/22 7:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RUBY
    Leadership Updates

    Live Leadership Updates

    See more

    $RUBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

      Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of

      11/2/22 4:01:00 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

      Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform.  www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo

      10/17/22 9:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

      BOSTON, July 19, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose "Pepe" Carmona to its Board of Directors. Mr. Carmona brings over 20 years of leadership experience in the biopharmaceutical industry across a range of roles and therapeutic areas. "We are thrilled to welcome Pepe to our Board of Directors," said Jonathan Montagu, Co-Founder and Chief Executive Officer of HotSpot Thera

      7/19/22 7:00:00 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics downgraded by Guggenheim

      Guggenheim downgraded Rubius Therapeutics from Buy to Neutral

      9/13/22 10:44:26 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

      SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $5.00 from $14.00 previously

      2/25/22 10:14:06 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

      SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $14.00 from $20.00 previously

      11/9/21 3:52:26 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care